Enterprise Value

147.5B

Cash

8.021B

Avg Qtr Burn

N/A

Short % of Float

0.51%

Insider Ownership

0.01%

Institutional Own.

16.88%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Andexxa (andexanet alfa) Details
Intracranial haemorrhage

Phase 4

Update

Calquence (acalabrutinib) Details
Cancer, Blood cancer, Chronic lymphocytic leukemia, Small lymphocytic lymphoma

Approved

Update

Approved

Update

Approved

Update

Enhertu Details
Cancer, Solid tumor/s

Approved

Quarterly sales

Beyfortus (Nirsevimab) Details
Respiratory syncytial virus, Respiratory virus, Viral infection

Approved

Quarterly sales

Lynparza w/ abiraterone and prednisone or prednisolone Details
Solid tumor/s, Cancer, Castration-resistant prostate cancer

Approved

Quarterly sales

Voydeya (Danicopan) Details
Paroxysmal nocturnal hemoglobinuria

Approved

Quarterly sales

Approved

Quarterly sales

Farxiga Details
Type 2 diabetes

Approved

Quarterly sales

Soliris (eculizumab) Details
Myasthenia gravis, Paroxysmal nocturnal hemoglobinuria , Atypical haemolytic uraemic syndrome

Approved

Quarterly sales

Approved

Quarterly sales

Imfinzi + Lynparza Details
Cancer, Solid tumor/s, Endometrial cancer

Approved

Quarterly sales

Approved

Quarterly sales

Tagrisso + chemotherapy Details
Lung cancer, Cancer, EGFR-mutated advanced lung cancer

Approved

Quarterly sales

Ultomiris Details
Rare diseases, Myasthenia gravis, Paroxysmal nocturnal hemoglobinuria , Atypical haemolytic uraemic syndrome, Neuromyelitis optica spectrum disorder (NMOSD)

Approved

Quarterly sales

Tagrisso Details
Cancer, Lung cancer, Non-small cell lung carcinoma

PDUFA

Approval decision

Dato-DXd (Datopotamab deruxtecan) Details
Lung cancer, Non-small cell lung carcinoma, Cancer

PDUFA

Approval decision

PDUFA

Approval decision

Imfinzi + chemotherapy (as neoadjuvant treatment) Details
Cancer, Non-small cell lung carcinoma, Lung cancer

PDUFA

Adcomm

NDA

Submission

Tozorakimab Details
Respiratory conditions, Acute respiratory distress syndrome, Lung disease

Phase 3

Data readout

LYNPARZA Details
Cancer, Solid tumor/s, Ovarian cancer

Phase 3

Data readout

Orpathys + Tagrisso Details
Cancer, Solid tumor/s

Phase 3

Data readout

Saphnelo Details
Idiopathic pulmonary fibrosis

Phase 3

Data readout

Dato-DXd Details
Cancer, Breast cancer

Phase 3

Data readout

LYNPARZA Details
Cancer, Solid tumor/s, Ovarian cancer

Phase 3

Data readout

Fasenra Details
Chronic rhinosinusitis with nasal polyps

Phase 3

Data readout

Phase 3

Data readout

Koselugo (selumetinib, MEK inhibitor) Details
Cancer, Solid tumor/s, Neurofibromatosis type 1

Phase 3

Data readout

Anselamimab (CAEL-101) Details
Amyloid light chain amyloidosis

Phase 3

Data readout

Tagrisso Details
Cancer, Lung cancer, Non-small cell lung carcinoma

Phase 3

Data readout

Imfinzi (durvalumab) Details
Cancer, Non-small cell lung carcinoma, Lung cancer

Phase 3

Data readout

Tezspire (tezepelumab) Details
Chronic rhinosinusitis with nasal polyps

Phase 3

Data readout

Imfinzi (mono/combo) Details
Cancer, Liver cancer

Phase 3

Data readout

Fasenra Details
Coronary Microvascular Dysfunction

Phase 3

Data readout

Phase 3

Update

Imfinzi comb w/ chemotherapy Details
Cancer, Gastroesophageal junction tumors, Gastric cancer

Phase 3

Update

roxadustat Details
Myelodysplastic syndrome, Anemia

Phase 3

Update

Enhertu Details
Breast cancer, Cancer

Phase 3

Update

Phase 3

Update

Imfinzi comb w/ chemotherapy Details
Cancer, Biliary Tract Cancer

Phase 3

Update

Imfinzi Details
Cancer, Bladder cancer

Phase 3

Update

Farxiga Details
Acute myocardial infarction

Phase 3

Update

Phase 3

Update

Capivasertib Details
Breast cancer, Cancer, Triple-negative breast cancer

Phase 3

Update

Imfinzi (durvalumab) Details
Lung cancer, Cancer, Small cell lung cancer

Phase 3

Update

Fasenra Details
Coronary Microvascular Dysfunction

Phase 3

Update

FPI-2265 Details
Prostate cancer, Cancer

Phase 2/3

Update

Phase 2b

Data readout

Dato-DXd (Datopotamab deruxtecan) Details
Non-small cell lung carcinoma, Cancer, Lung cancer

Phase 2

Data readout

Baxdrostat Details
Chronic kidney disease

Phase 2

Data readout

Baxdrostat Details
Primary aldosteronism

Phase 2

Data readout

Baxdrostat Details
Pulmonary hypertension

Phase 2

Data readout

Phase 2

Data readout

Anselamimab (CAEL-101) Details
Amyloid light chain amyloidosis

Phase 2

Data readout

Enhertu Details
Cancer, Non-small cell lung carcinoma

Phase 2

Update

Dato-DXd (Datopotamab deruxtecan) Details
Non-small cell lung carcinoma, Cancer, Lung cancer, Solid tumor/s, Triple-negative breast cancer

Phase 1/2

Data readout

LB-001 Details
Methylmalonic acidemia, Genetic disorder, Rare genetic disease

Phase 1/2

Interim update

ECC5004 Details
Obesity, Type 2 diabetes

Phase 1

Data readout

Phase 1

Data readout

Dato-DXd (Datopotamab deruxtecan) Details
Non-small cell lung carcinoma, Cancer, Lung cancer

Phase 1

Data readout

FPI-2059 Details
Solid tumor/s, Cancer

Phase 1

Update

Phase 1

Update

FPI-2068 Details
Solid tumor/s, Cancer

Phase 1

Update